{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:11:48Z","timestamp":1761844308641,"version":"3.41.2"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/igc.0000000000000051","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T04:35:27Z","timestamp":1390451727000},"page":"238-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Secondary Complete Cytoreduction in Recurrent Ovarian Cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"Enora","family":"Laas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Luyckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"De Cuypere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Selle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emile","family":"Dara\u00ef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Querleu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Rouzier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Ch\u00e9reau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0000000000000051_bb0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1438.2007.00826.x","article-title":"Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature","volume":"17","author":"Gadducci","year":"2007","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0000000000000051_bb0010","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer."},{"key":"10.1097\/IGC.0000000000000051_bb0015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am J Obstet Gynecol."},{"key":"10.1097\/IGC.0000000000000051_bb0020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0002-9378(92)91658-W","article-title":"Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?","volume":"166","author":"Hunter","year":"1992","journal-title":"Am J Obstet Gynecol."},{"key":"10.1097\/IGC.0000000000000051_bb0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer."},{"key":"10.1097\/IGC.0000000000000051_bb0030","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer."},{"key":"10.1097\/IGC.0000000000000051_bb0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdn591","article-title":"The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer","volume":"20","author":"Oksefjell","year":"2009","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jso.21491","article-title":"Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1Y1 cm after secondary cytoreduction","volume":"101","author":"Tian","year":"2010","journal-title":"J Surg Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2007.08.075","volume":"108","author":"Alberts","year":"2008","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0050","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0055","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ygyno.2009.04.037","article-title":"Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study","volume":"114","author":"Power","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/01.cco.0000174166.06734.c7","article-title":"The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence","volume":"17","author":"Harter","year":"2005","journal-title":"Curr Opin Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0065","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000658-199502000-00002","volume":"221","author":"Tian","year":"1995","journal-title":"Ann Surg."},{"key":"10.1097\/IGC.0000000000000051_bb0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000658-199502000-00002","article-title":"Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg."},{"key":"10.1097\/IGC.0000000000000051_bb0080","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/bjc.2011.328","article-title":"Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort","volume":"105","author":"Zang","year":"2011","journal-title":"Br J Cancer."},{"issue":"suppl 1","key":"10.1097\/IGC.0000000000000051_bb0085","first-page":"S122","article-title":"Cytoreductive surgery in recurrent ovarian cancer","volume":"130","author":"Loehr","year":"2004","journal-title":"J Cancer Res Clin Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0000000000000051_bb0095","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2004.07.045","article-title":"Factors associated with cytoreducibility among women with ovarian carcinoma","volume":"95","author":"Eltabbakh","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0100","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.20106","article-title":"Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?","volume":"100","author":"Zang","year":"2004","journal-title":"Cancer."},{"key":"10.1097\/IGC.0000000000000051_bb0105","first-page":"1193","article-title":"How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer [in Chinese]","volume":"22","author":"Li","year":"2003","journal-title":"Ai Zheng."},{"key":"10.1097\/IGC.0000000000000051_bb0110","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2007.04.006","article-title":"Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma","volume":"106","author":"Tebes","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejso.2004.08.016","article-title":"Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum","volume":"31","author":"Gronlund","year":"2005","journal-title":"Eur J Surg Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0120","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/jso.23094","article-title":"Secondary cytoreductive surgery outcomes of selected patients with paclitaxel\/platinum sensitive recurrent epithelial ovarian cancer","volume":"106","author":"Boran","year":"2012","journal-title":"J Surg Oncol."},{"key":"10.1097\/IGC.0000000000000051_bb0125","first-page":"1008","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"99","author":"Tay","year":"2002","journal-title":"Obstet Gynecol."},{"key":"10.1097\/IGC.0000000000000051_bb0130","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24022503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24022503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0000000000000051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:29:47Z","timestamp":1753223387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24022503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1048891X24022503"],"URL":"https:\/\/doi.org\/10.1097\/igc.0000000000000051","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary Complete Cytoreduction in Recurrent Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0000000000000051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.","name":"copyright","label":"Copyright"}]}}